Tang Jian, Chen Yu, Wang Chunhua, Xia Ying, Yu Tingyu, Tang Mengjun, Meng Kun, Yin Lijuan, Yang Yang, Shen Liang, Xing Hui, Mao Xiaogang
Central Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Medical Affairs, Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
MedComm (2020). 2024 Jul 28;5(8):e663. doi: 10.1002/mco2.663. eCollection 2024 Aug.
Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC-derived extracellular vesicles (MSCs-EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs-EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs-EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs-EVs in cancer treatment, along with the challenges they face.
间充质干细胞(MSCs)被恶性肿瘤细胞招募至肿瘤微环境(TME),并在恶性肿瘤的发生和发展中发挥关键作用。这一作用包括免疫逃逸、促进血管生成、刺激癌细胞增殖、与癌症干细胞的关联、在TME内的多向分化以及产生治疗抗性。同时,广泛的研究正在探索MSCs和MSCs衍生的细胞外囊泡(MSCs-EVs)在肿瘤中的归巢效应,旨在将它们设计为抗肿瘤物质的载体。这些物质被靶向递送抗肿瘤药物,以提高药物疗效,同时降低药物毒性。本文综述了MSCs在肿瘤进展中的支持作用及其相关分子机制。此外,我们总结了涉及工程化MSCs和MSCs-EVs在癌症治疗中的最新治疗策略,包括它们作为基因治疗剂、化疗药物和溶瘤病毒载体的应用。我们还讨论了MSCs和MSCs-EVs进入体内后的分布和清除情况,以阐明基于MSCs和MSCs-EVs的靶向治疗在癌症治疗中的潜力以及它们所面临的挑战。